

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/226019 A1

(51) International Patent Classification:
C07K 14/18 (2006.01) C12N 7/04 (2006.01)
C12N 15/86 (2006.01)

10210 Campus Point Dr., Suite #150, San Diego, California
92121 (US).

(21) International Application Number:
PCT/US2022/025470

(72) Inventor: **WANG, Nathaniel Stephen**; c/o Replicate Bio-
science, Inc., 10210 Campus Point Dr., Suite #150, San
Diego, California 92121 (US).

(22) International Filing Date:
20 April 2022 (20.04.2022)

(74) Agent: **DANG, David V.** et al.; One Financial Center,
BOSTON, Massachusetts 02111 (US).

(25) Filing Language: English

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(26) Publication Language: English

(30) Priority Data:
63/177,656 21 April 2021 (21.04.2021) US

(71) Applicants: **REPLICATE BIOSCIENCE, INC.**
[US/US]; 10210 Campus Point Dr., Suite #150, San Diego,
California 92121 (US). **MIYAKE-STONER, Shigeki**
Joseph; c/o Replicate Bioscience, Inc., 10210 Campus
Point Dr., Suite #150, San Diego, California 92121 (US).
CHOU, Annie Chia-Zong; c/o Replicate Bioscience, Inc.,

(54) Title: ALPHAVIRUS VECTORS CONTAINING UNIVERSAL CLONING ADAPTORS




FIG. 9

(57) Abstract: The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or replicons (*e.g.*, self-replicating RNAs), pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for modulating an immune response in a subject in need thereof, as well as methods for preventing and/or treating various health conditions.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*